标题：生物制剂在儿童哮喘治疗中应用进展

      作者：黄海燕 1，2 综述 卢根 1 审校    1.广州医科大学附属妇女儿童医疗中心呼吸科，广东 广州 510120；2.广州市荔湾中心医院儿科，广东 广州 510175

      卷次： 2024年35卷3期

      【摘要】 支气管哮喘(asthma)是一种以气流受限和气道高反应性为特征的气道慢性炎症性疾患，主要表现为反复发作的咳嗽、喘息、气促和胸闷，多数患儿可自行缓解或经抗哮喘治疗缓解。少数严重难治性哮喘患儿，经常规治疗方案不能缓解，哮喘反复发作加重可导致肺功能受损，生活质量下降。生物疗法是治疗这类严重哮喘的有效附加疗法，可显著降低哮喘的恶化发生率，改善患者的生活质量和哮喘控制率。本文将阐述目前临床治疗儿童严重哮喘的生物制剂。
      【关键词】 儿童；支气管哮喘；单克隆抗体；生物疗法；临床应用
      【中图分类号】 R725.6 【文献标识码】 A 【文章编号】 1003—6350（2024）03—0453—04

Research progress on the application of biologics in children with asthma.
HUANG Hai-yan 1, 2, LU Gen 1. 1. Departmentof Respiratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510120,Guangdong, CHINA; 2. Department of Pediatrics, Guangzhou Liwan Central Hospital, Guangzhou 510175, Guangdong,CHINA【Abstract】 Bronchial asthma is a chronic inflammatory disease of the airway characterized by airflow restrictionand airway hyperresponsiveness. It is mainly manifested by recurrent cough, wheezing, shortness of breath, and chesttightness. Most children can be relieved by themselves or by anti-asthma treatment. A small number of children with se-vere refractory asthma can not be relieved by conventional treatment, and repeated exacerbation of asthma can lead toimpaired lung function and decreased quality of life. Biotherapy is an effective additional treatment for this type of se-vere asthma, which can significantly reduce the incidence of asthma exacerbation and improve the quality of life andasthma control rate of patients. This article will describe the current clinical biologics for the treatment of severe asthmain children.
      【Key words】 Children; Bronchial asthma; Monoclonal antibodies; Biotherapy; Clinical application